Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase 1

Active, not recruiting

Conditions: Urothelial Carcinoma
Bladder Cancer

Interventions: Drug: Atezolizumab
Drug: Enfortumab Vedotin
Drug: Niraparib
Drug: Magrolimab (Hu5F9-G4)
Drug: Tiragolumab
Drug: Sacituzumab Govitecan
Drug: Tocilizumab
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2019-03-11

Last Posted Date: 2025-04-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 272

Registration Number: NCT03869190

Locations: 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇫🇷
Institut Claudius Regaud, Toulouse, France
🇺🇸
UCLA Department of Medicine, Los Angeles, California, United States

and more 31 locations

A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

Phase 1

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: Obinutuzumab
Drug: Atezolizumab
Drug: Cibisatamab
Drug: Tocilizumab

First Posted Date: 2019-03-07

Last Posted Date: 2024-08-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 47

Registration Number: NCT03866239

Locations: 🇫🇷
Centre Leon Berard; Departement Oncologie Medicale, Lyon, France
🇺🇸
Stanford Comprehensive Cancer Center, Stanford, California, United States
🇪🇸
START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid, Spain

and more 10 locations

A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Idasanutlin
Drug: Cytarabine
Drug: Daunorubicin
Procedure: Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)

First Posted Date: 2019-02-21

Last Posted Date: 2022-06-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 24

Registration Number: NCT03850535

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

and more 23 locations

A 2 Part Study to Assess the Relative Bioavailability of Tablet Formulation Compared to Capsule Formulation and the Effect of Food and Taste Assessment on the Tablet Formulation in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: RO7017773 Phase I Capsule
Drug: RO7017773 Phase II Tablet Unflavored
Drug: RO7017773 Phase II Tablet Sweetened/Flavored

First Posted Date: 2019-02-20

Last Posted Date: 2020-05-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 24

Registration Number: NCT03847987

Locations: 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

Phase 1

Completed

Conditions: Breast Cancer
Prostate Cancer
Ovarian Cancer

Interventions: Drug: Ipatasertib
Drug: Rucaparib

First Posted Date: 2019-02-15

Last Posted Date: 2023-10-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 51

Registration Number: NCT03840200

Locations: 🇦🇺
Macquarie University Hospital, Macquarie Park, New South Wales, Australia
🇪🇸
Clínica Universidad de Navarra, Pamplona, Navarra, Spain
🇮🇹
Azienda Ospedaliera Santa Maria di Terni, Terni, Umbria, Italy

and more 14 locations

An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies

Phase 3

Completed

Conditions: Huntington Disease

Interventions: Drug: RO7234292 (RG6042)

First Posted Date: 2019-02-15

Last Posted Date: 2023-08-31

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 236

Registration Number: NCT03842969

Locations: 🇪🇸
Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia, Barcelona, Spain
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
CenExel Rocky Mountain Clinical Research, LLC, Englewood, Colorado, United States

and more 35 locations

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

Phase 3

Completed

Conditions: Wet Macular Degeneration

Interventions: Drug: Faricimab
Drug: Aflibercept
Procedure: Sham Procedure

First Posted Date: 2019-01-30

Last Posted Date: 2023-02-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 671

Registration Number: NCT03823287

Locations: 🇵🇱
Dobry Wzrok Sp Z O O, Gdańsk, Poland
🇵🇱
Gabinet Okulistyczny Prof Edward Wylegala, Katowice, Poland
🇵🇱
SPEKTRUM Osrodek Okulistyki Klinicznej, Wroclaw, Poland

and more 156 locations

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

Phase 3

Completed

Conditions: Wet Macular Degeneration

Interventions: Drug: Faricimab
Drug: Aflibercept
Procedure: Sham Procedure

First Posted Date: 2019-01-30

Last Posted Date: 2023-01-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 658

Registration Number: NCT03823300

Locations: 🇦🇷
Centro Oftalmológico Dr. Charles S.A., Capital Federal, Argentina
🇵🇹
Hospital de Sao Joao; Servico de Oftalmologia, Porto, Portugal
🇺🇸
The Retina Care Center, Baltimore, Maryland, United States

and more 135 locations

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Phase 4

Completed

Conditions: Advanced Follicular Lymphoma

Interventions: Drug: Obinutuzumab
Drug: Bendamustine
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone/Prednisolone/Methylprednisolone
Drug: Vincristine

First Posted Date: 2019-01-28

Last Posted Date: 2024-04-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 114

Registration Number: NCT03817853

Locations: 🇳🇱
Albert Schweitzer Ziekenhuis - loc Dordrecht, Dordrecht, Netherlands
🇧🇷
NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, CE, Brazil
🇺🇸
San Juan Oncology Associates, Farmington, New Mexico, United States

and more 30 locations

Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Balovaptan therapeutic dose Treatment A
Drug: Balovaptan supra-therapeutic dose Treatment B
Drug: Active control [moxifloxacin] on Day 2 Treatment C
Drug: Active control [Moxifloxacin] on Day 15 Treatment D
Drug: Placebo for Balovaptan Treatment C
Drug: Placebo for Balovaptan Treatment D
Drug: Placebo for Moxifloxacin Treatment A
Drug: Placebo for Moxifloxacin Treatment B
Drug: Moxifloxacin Treatment C
Drug: Placebo for Moxifloxacin Treatment D
Drug: Moxifloxacin Treatment D
Drug: Placebo for Moxifloxacin Treatment C

First Posted Date: 2019-01-17

Last Posted Date: 2020-07-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 57

Registration Number: NCT03808298

Locations: 🇺🇸
PRA International Clinical Pharmacology Center (EDS US Clinic), Lenexa, Kansas, United States

Home Terms & Conditions Privacy Policy